Navigation Links
BioMS Medical to present at BioFinance 2009
Date:4/24/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, April 24 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, will present at BioFinance 2009 in Toronto.

    WHEN:  Wednesday April 29th at 11:00am (Eastern Time)

    WHERE: Toronto Marriott Eaton Centre Hotel (Trinity V room)
           525 Bay Street
           Toronto, ON

    About BioFinance 2009
    ---------------------

BioFinance 2009 is the leading investor conference in Canada for the life sciences and cleantech industries. This three-day event brings together key industry players interested in investment opportunities and issues affecting companies in the life sciences and cleantech sectors. Participants include senior life science executives, institutional and private equity investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the US and Europe. For more information visit http://www.biofinance.ca/

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... 30, 2015 Biodata, producer of ... integrated protocols and specimen management systems, and ChemAxon, ... consulting services for life science research, announce their ... newest feature: chemical structure and reaction support. Already ... biologists, bio-chemists, and more, the integration of ChemAxon's ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Agence de Medecine,Preventive (AMP) announced today the appointment ... SIVAC (Supporting Independent Immunization and,Vaccine Advisory Committees) initiative. ... national immunization technical advisory groups in six,resource poor ... committees will help,national health authorities to set up ...
... 12 Synvista Therapeutics, Inc. (NYSE Alternext ... BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of ... the effect of alagebrium on exercise tolerance in patients with ... enrollment of its BREAK ( B eginning a R ...
... ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) and ... a definitive agreement for Abbott to acquire AMO for $22 ... $2.8 billion, inclusive,of estimated net debt at the time of ... leader in ophthalmic care, comprised of three segments: cataract,surgery, laser ...
Cached Biology Technology:French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... University previously developed ion transistors for transport of both ... has now succeeded in combining both transistor types into ... electronics. An advantage of chemical circuits is ... various functions. This means that we now have new ...
... diseases, the St. Jude Children,s Research Hospital Washington ... release of comprehensive human cancer genome data for free ... information released more than doubles the volume of high-coverage, ... sources combined. This information is valuable not just to ...
... collaboration between scientists from the Experimental Therapeutics Centre (ETC) under ... from Tan Tock Seng Hospital (TTSH) has enabled the successful ... test kit available to date. With this highly advanced kit, ... H5N1 viruses in a single test with almost 100% accuracy, ...
Cached Biology News:World's largest release of comprehensive human cancer genome data helps speed discoveries 2World's largest release of comprehensive human cancer genome data helps speed discoveries 3Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 2Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 3